Predicting development of distant metastases and long-term outcome of locally advanced rectal cancer treated with neoadjuvant chemotherapy and radiation.
作者信息
Aschele Carlo, Negri Francesca
机构信息
Medical Oncology, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Gastroenterology and Endoscopy Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
出版信息
Ann Transl Med. 2022 Nov;10(21):1152. doi: 10.21037/atm-22-4307.
Abstract
摘要
相似文献
1
Predicting development of distant metastases and long-term outcome of locally advanced rectal cancer treated with neoadjuvant chemotherapy and radiation.
Ann Transl Med. 2022 Nov;10(21):1152. doi: 10.21037/atm-22-4307.
2
[Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Nov 25;24(11):998-1007. doi: 10.3760/cma.j.cn441530-20210927-00386.
3
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
4
[Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):274-280. doi: 10.3760/cma.j.cn.441530-20190819-00312.
5
Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer.
BMC Cancer. 2019 Dec 16;19(1):1222. doi: 10.1186/s12885-019-6424-4.
6
mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Clin Colorectal Cancer. 2022 Mar;21(1):e12-e20. doi: 10.1016/j.clcc.2021.11.009. Epub 2021 Nov 28.
7
College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Oncologist. 2021 May;26(5):e780-e793. doi: 10.1002/onco.13707. Epub 2021 Feb 22.
8
Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes.
Rev Esp Enferm Dig. 2020 Jan;112(1):16-22. doi: 10.17235/reed.2019.6454/2019.
9
Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
Jpn J Clin Oncol. 2021 Aug 30;51(9):1391-1399. doi: 10.1093/jjco/hyab095.
10
[pCR Achievement in Two Cases Treated with XELOXIRI as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer].
Gan To Kagaku Ryoho. 2020 Mar;47(3):484-486.
本文引用的文献
1
Development and external validation of prognostic nomograms for liver disease-free and overall survival in locally advanced rectal cancer with neoadjuvant therapy: a post cohort study based on the FOWARC trial.
Ann Transl Med. 2022 Jun;10(12):694. doi: 10.21037/atm-22-2790.
2
A prognostic nomogram for stage II/III rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgical resection.
BMC Surg. 2022 Jul 4;22(1):256. doi: 10.1186/s12893-022-01710-z.
3
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
4
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7.
5
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial.
J Clin Oncol. 2019 Dec 1;37(34):3223-3233. doi: 10.1200/JCO.18.02309. Epub 2019 Sep 26.
6
Hepatocytes direct the formation of a pro-metastatic niche in the liver.
Nature. 2019 Mar;567(7747):249-252. doi: 10.1038/s41586-019-1004-y. Epub 2019 Mar 6.
7
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.
Lancet. 2018 Jun 23;391(10139):2537-2545. doi: 10.1016/S0140-6736(18)31078-X.
8
Abdominoperineal Resection for Rectal Cancer in the Twenty-First Century: Indications, Techniques, and Outcomes.
J Gastrointest Surg. 2018 Aug;22(8):1477-1487. doi: 10.1007/s11605-018-3750-9. Epub 2018 Apr 16.
9
Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
J Gastrointest Oncol. 2017 Feb;8(1):39-48. doi: 10.21037/jgo.2016.11.03.
10
Extravascular red blood cells and hemoglobin promote tumor growth and therapeutic resistance as endogenous danger signals.
J Immunol. 2015 Jan 1;194(1):429-37. doi: 10.4049/jimmunol.1400643. Epub 2014 Nov 26.
Zotero 插件